Research ArticleCancer

Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity

See allHide authors and affiliations

Science Translational Medicine  16 Sep 2020:
Vol. 12, Issue 561, eaba5464
DOI: 10.1126/scitranslmed.aba5464

Hidden virtues of interleukin-2

Interleukin-2 (IL-2) is an immunostimulatory cytokine that is being tested as an anticancer therapy due to its ability to activate T cells and natural killer cells. Unexpectedly, Raeber et al. discovered that IL-2 can also activate dendritic cells, an entirely different type of cells involved in antitumor immunity. The authors analyzed data from a clinical trial in human patients being treated with recombinant IL-2. They also pursued more detailed studies in mouse models to identify the mechanisms responsible for dendritic cell activation, helping to explain how IL-2 sensitizes tumors to immune destruction.

View Full Text

Stay Connected to Science Translational Medicine